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Objective: to analyse the clinical outcome of patients with ischaemic ulcers (Fontaine stage IV) undergoing percutaneous
transluminal angioplasty (PTA).
Methods and design: retrospective cohort study of 40 patients (21 males) treated between January 1998 and December
1998. Cardiovascular risk factors, co-morbid, baseline laboratory, angiographic data and technical success were recorded.
Patients were followed for a median of 20 (inter quartile range {IQR} 8±26) months.
Results: cumulative ulcer healing rates at 3, 6, 12, and 24 months were 15, 40, 54 and 81%, respectively. The median time
to healing was 5 (IQR 2±7) months. Cumulative restenosis at 1, 3, 6 and 12 months was 3, 10, 29 and 52%, respectively.
Nine patients (22%) suffered ulcer reappearance. Lipoprotein (a) serum levels 430 mg/dl (HR 0.2, 95% CI 0.05±1.0,
p 0.05) and diabetes mellitus (HR 0.2, 95% CI 0.5±0.7, p 0.01) were associated with delayed ulcer healing.
Conclusion: PTA leads to ulcer healing in the majority of patients. Elevated lipoprotein (a) levels 430 mg/dl and diabetes
mellitus are independently associated with ulcer persistence.
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Symptomatic peripheral artery disease (PAD) affects
3±6% of all patients over 60 years of age.1±3 Critical
limb ischaemia occurs in approximately 5% of these
patients within 5 years from initial symptoms and
causes considerable morbidity and costs.1,4±8 Persis-
tent ulceration, osteomyelitis or gangrene frequently
necessitate major surgical revision or amputation.9±11
Multi-segmental vessel lesions and extensive involve-
ment of crural arteries characterise the atherosclerotic
vascular changes in these patients.1,12 Patients with
diabetes mellitus have a two to threefold increased
risk for development of ischaemic ulcers compared
to non-diabetics.1,13,14
Chronic critical limb ischaemia may be treated
conservatively, surgically or by percutaneous endo-
vascular procedures.15±23 The major disadvantage of
the surgery is the invasiveness of the procedure and
the peri-operative risk.1 However, only approximately
20±30% of patients with affected crural arteries havePlease address all correspondence to: W. Mlekusch, Department
of Internal Medicine II, Division of Angiology, Vienna General
Hospital, Medical School, WaÈhringer GuÈ rtel 18-20, A-1090 Vienna,
Austria.
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angioplasty.24±26 Furthermore, the rate of restenosis
after endovascular treatment is high. Therefore,
PTA has been considered primarily for patients with
limited disease.24,26,27 Data concerning endovascular
treatment of patients with extensive multi-segmental
PAD and critical limb ischaemia are limited.
The aim of the study was to analyse the clinical
outcome of patients with extensive multi-segmental
peripheral artery disease and ischaemic ulcers
(Fontaine stage IV) undergoing percutaneous trans-
luminal angioplasty (PTA) in the femoropopliteal
region. Primary endpoint was ulcer healing. Further-
more, prognostic parameters for ulcer persistence
were assessed in these patients.
Material and Methods
Study design
This was a retrospective study of all patients with
multi-segment PAD and ischaemic ulcers (Fontaine
stage IV) who underwent femoropopliteal PTA
between January 1998 and December 1998. Patientsrights reserved.
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iliac disease were also included.
The study was performed according to the
Declaration of Helsinki.
Definitions
Hypercholesterolaemia was defined as baseline serum
cholesterol above 5.2 mmol/l or serum LDL above
3.4 mmol/l. Diabetes mellitus was classified in
patients with a history of diabetes and in patients
with a HbA1c level above 6.5%. Arterial hypertension
was diagnosed according to the WHO criteria.
Patients who were smoking 43 cigarettes daily, were
regarded as current smokers.
Poor run off was defined as either occlusion or
significant stenosis of the femoral or popliteal artery
distal to the treated segment and/or in patients
with occlusions of at least two crural arteries.
An occlusion/stenosis length up to 5 cm was defined
as short lesion, otherwise as a long lesion. Trophic
ischaemic lesions with a diameter below 4 cm and
a depth below 0.5 cm were classified as minor
ulceration, all other ulcers were defined major ulcer-
ation. Amputation of a toe or mesh-graft implanta-
tion was classified as minor surgery. Major surgery
was defined as bypass-implantation or any other
amputation.
Patient data
Demographic and interventional data were recorded
retrospectively by systematic review of patients charts
and review of the PTA registry. Patients age, sex,
atherothrombotic risk factors and cardiovascular
co-morbidities were documented. Routine laboratory
parameters at admission included complete blood
count, leucocytes, serum creatinin, C-reactive protein,
HbA1c, fibrinogen, lipoprotein (a), total cholesterol,
low density lipoprotein (LDL) cholesterol, high den-
sity lipoprotein (HDL) cholesterol, triglycerides and
uric acid. Pre- and postinterventional ankle±brachial
index was recorded. Colour coded duplex examina-
tions were performed at baseline and 24 h after the
intervention (5 MHz, linear array colour probe [model
XP 10; Acuson, Mountain View, CA, U.S.A.]) and if
necessary at any other follow up visit. The maximum
peak systolic velocity (PSV) in the dilated region was
determined and compared to the PSV in the preceding
normal segment. A focal increase in the PSV of at least
140% (corresponding to a peak velocity ratio [PVR]
of 2.4) was considered indicative of a stenosis ofgreater than 50% at that site. Peri-interventionally all
patients received twice daily intravenous Prosta-
glandin E1 (40 mg Alprostadil, Prostavasin, Gebro
Fieberbrunn, Austria) during a time interval of 10±14
days. All patients received a long-term antiplatelet
therapy with acetylsalicylic acid 100 mg once daily.
Follow up
After PTA, all patients were invited routinely at 1, 3, 6
and 12 months for follow-up investigations and there-
after annually. Follow-up investigations consisted of
oscillography, Doppler measurements and clinical
investigation. Patients with new onset of claudication
or increase of complaint as well as patients with signi-
ficant reduction of ankle±brachial index (deterioration
by at least 0.15 from the maximum postprocedural
level) were further evaluated with colour coded
duplex sonography.28±30 Patients with incompressible
arteries and unjudgeable ABI due to mediasclerosis
underwent oscillography and measurment of arterial
toe-pressure to stage the disease. Non-compressibility
was assessed by missing or hardly detectable pressure
decrease during proximal compression. In these
patients arterial toe pressure was used for calculation
of the ABI. Patients were followed until ulcer healing
or, in case of ulcer persistence, until the end of the
study period. Re-occurrence of ulcers is not included
in the life table analysis.
All patients showed a multi-segmental disease with
obstructive target lesions in the femoro-popliteal seg-
ment. Thirty-two patients had two patent arteries and
8 patients showed one patent crural artery, no patient
had three patent arteries in the crural section. How-
ever, patients with persistent ulceration were followed
in two weeks intervals at the outpatient ward of the
department until ulcer healing. Restenosis was
defined as a 50% diameter reduction at the dilated
segment. The rate of restenosis was assessed by colour
coded duplex sonography and follow up angiograms,
if available.
Statistical methods
Continuous data are presented as the median and
interquartile range (range from the 25th to the 75th
percentile). Percentages were calculated for dicho-
tomous variables. The Wilcoxon test was used for
comparison of continues, paired variables. The
course of ulcer healing after PTA was assessed using
Kaplan±Meier curves and life table analysis. The
Log Rank test was used for univariate comparisonEur J Vasc Endovasc Surg Vol 24, August 2002
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hazard model was applied to assess independent
predictors for ulcer healing and to adjust for
confounding factors. All p-values are two sided,
a p-value50.05 was accepted as statistically signi-
ficant. Calculations were performed using SPSS for
Windows (Version 10.0).
Results
Forty eligible patients were treated within the one
year period, all patients were included in the
study. The median age was 74 years (IQR 65±80).
Demographic data shown in Table 1.
Median diameter of the ischaemic ulcers was 2 cm
(IQR 1±4). Minor ulceration was found in 25 patients
(62%), major ulceration was observed in 15 patients
(38%). The majority of ulcers was found located at
the toes (n 25, 62%). Ulceration persisted for at
least 3 months prior to intervention.
Additional to endovascular procedures in the
femoro-popliteal segment a PTA in crural arteries
was performed in 14 patients (37%). No stent implant-
ation was performed in the crural arteries. Additional
PTA and stent implantation in the iliac artery was
performed in 3 patients (7%).
The median grade of stenosis of the treated femoro-
popliteal segment was 80% (IQR 74±100). The median
length of the treated occlusion/stenosis was 5 cm
(IQR 4±7). Complete occlusion in the femoropopliteal
segment was detected in 11 patients. The median
pre-interventional ankle±brachial index (ABI)
was 0.32 (0.23±0.38). Not compressible arteries due to
mediasclerosis were found in 21 patients (53%).
Peri-interventional complications occurred in
7 patients (three vessel-dissections and four post-
interventional bleedings). All bleeding complications
were treated conventionally by manual compression.
The ABI improved significantly post-interventionally
to median 0.7 (IQR 0.51±0.76) (p50.0001). After PTA,
residual stenosis (430%) at the dilated segment was
found in 25 cases (62%) 24 h after PTA assessed by
colour coded duplex sonography.Table 1. Multivariate Cox proportional hazard model assessing the
risk for ulcer healing within the median observation period of 20
months (IQR 8±26).
HR 95% CI p-value
Age (1 year increments) 1.0 0.9±1.0 0.5
Male sex 1.1 0.5±2.7 0.8
Lipoprotein(a) 430 mg/dl 0.2 0.05±1.0 0.05
Diabetes mellitus 0.2 0.5±0.7 0.01
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The median follow-up interval was 20 months
(IQR 8±26). None of the patients died or were lost
during the follow-up period. Minor surgery was per-
formed in 9 patients (22%) and 4 patients (10%) under-
went major surgery. Healing of trophic lesions within
the follow-up period was found in 24 patients (60%).
The median healing interval was 5 months (IQR 2±7)
(Fig. 1). Cumulative healing rates at 3, 6, 12, and 24
months were 15, 40, 54 and 81%, respectively. A re-
appearance of ulcers was found in 9 patients (22%).
Univariate comparison of risk factors for ulcer
persistence showed that patients with diabetes had
a significantly reduced healing rate (Log Rank
p 0.03). Patients with elevated lipoprotein(a)
430 mg/dl had a trend towards a reduced healing
rate (Log rank p 0.1). Length of the dilated lesion,
grade of stenosis, residual stenosis at the dilated
segment, number of crural vessels and procedure
complications were not associated with ulcer healing
in this patient series. Patients age, gender, athero-
sclerotic co-morbidities (coronary artery disease,
carotid artery stenosis) and the atherothrombotic risk
factors smoking, arterial hypertension and hyperlipi-
daemia showed also no association with ulcer healing
(Table 2). In the present patient series lipoprotein(a)
levels were not associated with restenosis (p 0.8).
A multivariate Cox proportional hazard model was
applied to assess the independent effect of vascular
risk factors on ulcer healing and to adjust for patients
age and sex. Diabetes mellitus and elevated
levels of lipoprotein(a) 430 mg/dl were inverselyFig. 1. Healing of ischaemic ulceration in patients with multi-
segmental peripheral artery disease Fontaine IV after endovascular
revascularisation.
Table 3. Life table calculated by the Kaplan±Meier method.
Time
interval
Patients
at risk
Cumulative
restenosis rate
Standard
error
1 month 40 1 (3%) 0.025
3 months 34 4 (10%) 0.079
6 months 26 11 (29%) 0.190
12 months 16 21 (52%) 0.136
Table 2. Demographic data of 40 patients with ischaemic
ulceration of the lower limb and endovascular treatment of the
femoro-popliteal segment.
Patients with
ulcer healing
(n 24, 60%)
Patients without
ulcer healing
(n 16, 40%)
p-value
Female sex 11 (28%) 8 (20%) 0.7
Arterial hypertension 16 (43%) 6 (15%) 0.2
Diabetes mellitus 20 (50%) 12 (30%) 1.0
Habitual smokers 11 (28%) 6 (15%) 1.0
Coronary heart disease 15 (38%) 5 (13%) 0.2
Carotid artery
plaques/stenosis
6 (15%) 6 (15%) 0.3
Hyperlipidaemia 11 (28%) 4 (10%) 0.3
25% luminal narrowing.
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ulcer persistence (Table 1).
Cumulative rates of restenosis after 1, 3, 6 and 12
months were 3, 10, 29 and 52%, respectively (Table 3).
A re-intervention after a median interval of 5 months
(IQR 3±8) was performed in 15 patients (37%). The
need for re-intervention was not associated with
altered healing rates (Log rank p 0.5), since all
reintervention successfully restored vessel patency.
Similarly, primary restenosis (n 21/40) showed no
significant association with ulcer healing during the
observation period. Similarly, primary restenosis
(n 21/40) showed no significant association with
ulcer healing, since reinterventions were per-
formed in the majority of these patients (n 15/21)
to restore vessel patency. Similarly, primary restenosis
(n 21/40) showed no significant association with
ulcer healing during the observation period.
Discussion
A majority of patients with multi-segmental peri-
pheral artery disease and chronic critical limb
ischaemia can be successfully treated with PTA.
Ischaemic ulcers in patients with diabetes mellitus and
elevated serum levels of lipoprotein(a) 430 mg/dl
showed a lower rate of healing.
All patients in this study were elderly and frequently
suffered several co-morbidities, but remarkably noneof these patients died within the follow up period.
However, in many cases surgical revascularisation
would not have been feasible with acceptable peri-
operative risk. In particular, costly crural reconstruc-
tions frequently would have been necessary, as crural
arteries were affected in all patients. PTA is less
invasive and risky. However, technical success in
these patients often remains unsatisfactory, which is
indicated by the high proportion of patients with
residual stenosis at the dilated segment 24 h after the
intervention. Nevertheless, even partial restoration
of distal blood supply after PTA may initiate ulcer
healing. The median healing interval of 5 months
after successful revascularisation compares well to
the literature.27,31,32 Remarkably, even in this series
of patients with severe vessel morphology treatment
success in terms of ulcer healing was observed
frequently.
The finding that diabetes was a risk factor for
ulcer persistence is in line with published data.33±35
Arterial occlusive disease in diabetics is characterised
by macroangiopathy frequently affecting the crural
arteries extensively36 as well as microangiopathy.
Macroangiopathy may be treated successfully by
means of PTA restoring blood flow in the large arteries
in the proximal crural segments. Persistent haemo-
dynamic impairment in the distal crural arteries in
diabetic patients leads to significantly reduced ulcer
healing rates compared to patients with isolated
non-diabetic macroangiopathy.28,37,38
Lower patency rates were found previously in
patients with elevated levels of lipoprotein(a)39 and
thus may cause reduced ulcer healing, however in
the present patient series no association between
lipoprotein(a) levels and restenosis were observed.
Furthermore, increased lipoprotein(a) serum levels
are associated with endothelial dysfunction and vaso-
constriction in patients with atherosclerosis.40±42
This may also contribute to a reduced compensatory
haemodynamic reserve and increased risk for ulcer
persistence.
Primary restenosis was not associated with ulcer
healing. This may be explained by the fact, that the
majority of these patients successfully underwent
reinterventions and sustained vessel patency was
achieved in this patients during the observation
period.
Limitations
The retrospective study design implies some limita-
tions. However, due to a strict peri-intervention proto-
col at our department and strict follow-up intervals,Eur J Vasc Endovasc Surg Vol 24, August 2002
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patient had to be excluded from the analysis. Patients
were identified by our PTA registry, which records all
endovascular interventions. Due to the retrospective
study design we were not able to completely clarify
the pathogenesis of ulcers, particularly, segregation
between neuropathic and ischaemic pathogenesis of
the ulcers is difficult. However, extensive arterial
obstructions were found in all patients implicating
that ischaemia played a pivotal role in the patho-
genesis of these ulcers. The median ABI of 0.32
referred just to patients without media calcification,
including all patients the median ABI was 0.4 (includ-
ing patients with media sclerosis). This indicates that
patients with media sclerosis also had reduced ABI
and haxemodynamical relevant atherosclerotic
lesions.
Diabetes mellitus is an established risk factor for
peripheral artery disease, lower limb ulceration.33±35
In the present patient series a high incidence of
diabetes was found (80%) and the finding that
diabetes is a risk factor for ulcer persistence is in line
with published data.33±35
Due to the combination of PTA and PGE1 it is in fact
impossible to exactly separate the treatment effects
of PTA and PGE1. Therefore our conclusion on lipo-
protein(a) and ulcer healing refer to the combined
treatment of PTA and PGE1, which we considered
superior to PTA alone.
Conclusion
Peripheral percutaneous transluminal angioplasty
may restore sufficient distal blood flow for ulcer heal-
ing in selected patients with severe multi-segmental
vessel lesions. Diabetes mellitus and elevated
lipoprotein(a) levels 430 mg/dl were independently
associated with an increased risk for ulcer persistence.
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